New drug cocktail shows promise for Tough-to-Treat myeloma
NCT ID NCT03763162
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 29 times
Summary
This study tests a two-step treatment plan for people with multiple myeloma that has come back or stopped responding to therapy. First, patients receive a combination of daratumumab, bortezomib, and dexamethasone, then switch to daratumumab, ixazomib, and dexamethasone. The goal is to see if this approach helps control the cancer longer. About 40 adults with measurable disease are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.